Northeast Financial Consultants’s Bristol-Myers Squibb BMY Stock Holding History

Northeast Financial Consultants’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$1.72M	Sell	37,186 -1,686	-4%	-$82.8K	0.07%	117
2025 Q1	$2.37M	Sell	38,872 -2,935	-7%	-$171K	0.11%	98
2024 Q4	$2.36M	Buy	41,807 +1	+0%	+$56	0.1%	95
2024 Q3	$2.16M	Buy	41,806 +1	+0%	+$47	0.09%	98
2024 Q2	$1.74M	Sell	41,805 -3,575	-8%	-$160K	0.08%	109
2024 Q1	$2.46M	Buy	45,380 +3,201	+8%	+$163K	0.12%	97
2023 Q4	$2.16M	Sell	42,179 -807	-2%	-$42.4K	0.12%	97
2023 Q3	$2.49M	Buy	42,986 +1	+0%	+$61	0.16%	93
2023 Q2	$2.75M	Hold	42,985	–	–	0.17%	87
2023 Q1	$2.98M	Sell	42,985 -75	-0.2%	-$5.29K	0.19%	78
2022 Q4	$3.1M	Hold	43,060	–	–	0.21%	76
2022 Q3	$3.06M	Sell	43,060 -5,399	-11%	-$392K	0.22%	69
2022 Q2	$3.73M	Sell	48,459 -334	-0.7%	-$25.4K	0.26%	63
2022 Q1	$3.56M	Buy	48,793 +77	+0.2%	+$5.17K	0.21%	70
2021 Q4	$3.04M	Sell	48,716 -3,652	-7%	-$214K	0.18%	70
2021 Q3	$3.1M	Sell	52,368 -7,345	-12%	-$484K	0.21%	70
2021 Q2	$3.99M	Buy	59,713 +937	+2%	+$61.1K	0.27%	58
2021 Q1	$3.71M	Sell	58,776 -935	-2%	-$58.2K	0.28%	56
2020 Q4	$3.7M	Sell	59,711 -17,618	-23%	-$1.08M	0.31%	53
2020 Q3	$4.66M	Buy	77,329 +225	+0.3%	+$13.5K	0.42%	39
2020 Q2	$4.53M	Buy	77,104 +23,902	+45%	+$1.43M	0.44%	39
2020 Q1	$2.96M	Sell	53,202 -199	-0.4%	-$12.2K	0.34%	54
2019 Q4	$3.43M	Buy	53,401 +4,534	+9%	+$260K	0.31%	62
2019 Q3	$2.48M	Buy	48,867 +2	+0%	+$94	0.25%	76
2019 Q2	$2.22M	Buy	48,865 +3,302	+7%	+$154K	0.23%	75
2019 Q1	$2.17M	Buy	45,563 +2	+0%	+$100	0.24%	67
2018 Q4	$2.37M	Buy	+45,561	New	+$2.45M	0.33%	56
2017 Q2	–	Sell	-4,152	Closed	-$226K	–	143
2017 Q1	$226K	Sell	4,152 -2,821	-40%	-$155K	0.09%	136
2016 Q4	$407K	Sell	6,973 -1,500	-18%	-$82K	0.18%	97
2016 Q3	$456K	Buy	+8,473	New	+$544K	0.19%	94

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northeast Financial Consultants's BMY Position: Q2 2025 in Review

Northeast Financial Consultants reduced its Bristol-Myers Squibb (BMY) stake by 4.3% in Q2 2025, selling an estimated $82.8K and leaving 37,186 shares worth $1.72M. The position accounts for 0.07% of the portfolio, ranked #117.

Northeast Financial Consultants first reported a position in BMY in Q3 2016 and has held it in 30 quarters since. The position peaked at $4.66M in Q3 2020. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

Northeast Financial Consultants held 37,186 shares of Bristol-Myers Squibb worth $1.72M as of Q2 2025.
Northeast Financial Consultants sold 1,686 Bristol-Myers Squibb shares in Q2 2025, an estimated $82.8K.
Bristol-Myers Squibb made up 0.07% of Northeast Financial Consultants's portfolio in Q2 2025, its #117 holding.
Northeast Financial Consultants first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 30 quarters since.
Northeast Financial Consultants's Bristol-Myers Squibb position peaked at $4.66M in Q3 2020.
2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.